Related Experiment Video
Updated: Sep 4, 2025

Exploring the Two Herb Combination Strategy to Treat Injured PC12 Cells
Published on: November 18, 2022
Icariside Ⅱ Attenuates Palmitic Acid-Induced Endothelial Dysfunction Through SRPK1-Akt-eNOS Signaling Pathway
Yang-Yang Gu1,2,3, Xiao-Hui Tan2,3,4, Wen-Peng Song2,3,5
1Department of Radiation Medicine, Institute of Systems Biomedicine, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China.
Abstract:
Background: Endothelial dysfunction is commonly accompanied by a reduced capacity for nitric oxide (NO) production and decreased NO sensitivity, playing a central role in numerous vascular diseases. Saturated free fatty acids are known to reduce NO production and then induce endothelial dysfunction. Alternative splicing participates in the regulation of cellular and tissular homeostasis and is highly regulated by serine-arginine protein kinase (SRPK1). The role of SRPK1 in the biology of endothelial cells remains elusive. Icariside Ⅱ (ICA Ⅱ) has been reported to have protective effects on endothelial function. However, the specific molecular mechanisms are still unknown. The purpose of this study is to explore the role of SRPK1 in the biology of endothelial cells and the underlying mechanism of ICA Ⅱ on palmitic acid (PA) induced endothelial dysfunction. Methods: Endothelial dysfunction was induced using PA in human umbilical vein endothelial cells (HUVECs). The expression and phosphorylation of related proteins in the SRPK1-Akt-eNOS signaling pathway were detected by Western Blot. Cell Counting Kit-8 assay and Ki-67 immunofluorescence were used to estimate cell viability. Endothelial cell function was assessed by detecting NO production using DAF-FM DA. Interaction between ICA Ⅱ and SRPK1 was demonstrated by a biotinylated protein interaction pull-down assay. Results: The expressions of eNOS, Akt, and SRPK1 were down-regulated in the endothelial dysfunction stimulated by PA. SRPK1 inhibitor SPHINX31 restrained endothelial cell viability in a dose-dependent manner. Moreover, inhibition of SRPK1 using SPHINX31 and knockdown of SRPK1 by shRNA also showed a down-regulation of the proteins associated with the SRPK1-Akt-eNOS signaling pathway. Biotinylated protein interaction pull-down assay revealed that ICA Ⅱ could be directly bound with SRPK1. On the other hand, ICA Ⅱ could attenuate the PA-induced endothelial dysfunction and restore cell viability through the SRPK1-Akt-eNOS pathway. Conclusions: ICA Ⅱ, bound with SRPK1, could attenuate the endothelial dysfunction induced by the PA in HUVECs via the SRPK1-Akt-eNOS signaling pathway.
Insights
Icariside II (ICA II) protects against palmitic acid-induced endothelial dysfunction by binding to serine-arginine protein kinase 1 (SRPK1). This interaction restores nitric oxide (NO) production and cell viability via the SRPK1-Akt-eNOS pathway.
Area of Science:
- Vascular Biology and Endothelial Function
- Molecular Signaling Pathways
- Pharmacology and Natural Products
Background:
- Endothelial dysfunction, characterized by reduced nitric oxide (NO) production and sensitivity, is central to vascular diseases.
- Saturated free fatty acids, like palmitic acid (PA), induce endothelial dysfunction.
- Serine-arginine protein kinase 1 (SRPK1) regulates alternative splicing and its role in endothelial cells is unclear; Icariside II (ICA II) may offer protection.
Purpose of the Study:
- To elucidate the role of SRPK1 in endothelial cell biology.
- To investigate the protective mechanism of ICA II against PA-induced endothelial dysfunction.
Main Methods:
- Human umbilical vein endothelial cells (HUVECs) were treated with PA to induce dysfunction.
- Western Blotting assessed protein expression and phosphorylation in the SRPK1-Akt-eNOS pathway.
- Cell viability was measured using CCK-8 and Ki-67 assays; NO production was detected by DAF-FM DA; protein interactions were confirmed via pull-down assays.
Main Results:
- PA treatment downregulated eNOS, Akt, and SRPK1 expression in HUVECs.
- SRPK1 inhibition (SPHINX31) or knockdown (shRNA) reduced cell viability and downstream signaling proteins.
- ICA II directly bound to SRPK1 and attenuated PA-induced endothelial dysfunction, restoring cell viability through the SRPK1-Akt-eNOS pathway.
Conclusions:
- ICA II directly interacts with SRPK1.
- ICA II mitigates PA-induced endothelial dysfunction in HUVECs.
- The protective effects of ICA II are mediated via the SRPK1-Akt-eNOS signaling pathway.
More Related Videos
Related Concept Videos
cAMP-dependent Protein Kinase Pathways
PI3K/mTOR/AKT Signaling Pathway
The JAK-STAT Signaling Pathway
Antihypertensive Drugs: Direct Renin Inhibitors
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
GPCR Desensitization

